

July 25, 2023

Company Name	Otsuka Holdings Co., Ltd.
Name of Representative	Tatsuo Higuchi President and Representative Director, CEO
Code Number	4578, Prime market of the Tokyo Stock Exchange
Contact	Yuji Kogure Director, Investor Relations Department (Phone: +81-3-6361-7411)

Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2023

Based on our recent business results, Otsuka Holdings Co., Ltd. (the “Company”) hereby revised our consolidated financial forecasts for the first half of FY2023, previously announced on February 14, 2023.

1. Revision of the consolidated financial forecasts for the first half of FY2023

	Revenue	Business profit	Operating profit	Profit before tax	Profit for the period	Profit attributable to owners of the Company	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast (A)	867,000	92,500	91,500	91,000	70,000	68,000	125.31
Revised forecast (B)	947,500	155,000	130,500	138,800	105,000	102,500	189.00
Amount of change (B-A)	80,500	62,500	39,000	47,800	35,000	34,500	
Change (%)	9.3%	67.6%	42.6%	52.5%	50.0%	50.7%	
(Reference) Consolidated results for the first half of FY2022	814,307	78,126	67,146	92,788	71,524	69,770	128.57

Note:

Due to the application of IAS 12 “Income Taxes” (amended in May 2021), results for the six-month period ended June 30, 2022, have been retrospectively restated.

2. Reasons for the revision

For the six-month period ended June 30, 2023, revenue was strong in all operating segments. In particular, business performance was driven by sales growth of the four global products, the long acting antipsychotic agent *ABILIFY MAINTENA*, the antipsychotic agent *REXULTI*, the V₂-receptor antagonist *JYNARQUE*, and the anti-cancer agent *LONSURF*, and royalties and milestones for out-licensed products, etc. in the pharmaceutical business, and by sales growth of *Nature Made* in the nutraceutical business. Furthermore, business performance is progressing ahead of the plan, even if the impact of the depreciation of the yen is excluded.

As a result, revenue, business profit, operating profit, profit for the period and profit attributable to owners of the Company are expected to exceed the previously announced forecasts. The Company plans to announce the forecast of

consolidated financial results for the fiscal year ending December 31, 2023 when it announces the financial results on July 31, 2023.

Note:

The above forecasts are based on information available and certain assumptions that the Company deems reasonable at the time of the announcement. Actual operating results may differ from these projections due to various factors.